



## Complete Summary

---

### GUIDELINE TITLE

Thromboembolism in pregnancy.

### BIBLIOGRAPHIC SOURCE(S)

American College of Obstetricians and Gynecologists (ACOG). Thromboembolism in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2000 Aug. 10 p. (ACOG practice bulletin; no. 19). [73 references]

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Thromboembolism in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 1997 Mar. (ACOG educational bulletin number 234).

According to the guideline developer, this guideline is still considered to be current as of December 2005, based on a review of literature published that is performed every 18-24 months following the original guideline publication.

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
CONTRAINDICATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT  
CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

Venous thromboembolism during pregnancy, including deep vein thrombosis (DVT) and pulmonary embolism (PE)

## GUIDELINE CATEGORY

Management  
Prevention  
Risk Assessment  
Treatment

## CLINICAL SPECIALTY

Family Practice  
Internal Medicine  
Obstetrics and Gynecology  
Pulmonary Medicine

## INTENDED USERS

Physicians

## GUIDELINE OBJECTIVE(S)

- To aid practitioners in making decisions about appropriate obstetric and gynecologic care
- To review the current literature on the prevention and management of thromboembolism in obstetric patients, discuss the data behind sometimes conflicting guidelines from expert panels, and offer evidence-based recommendations to address the most clinically relevant issues in the management of these patients

## TARGET POPULATION

Pregnant women at risk of venous thromboembolism

## INTERVENTIONS AND PRACTICES CONSIDERED

1. Thromboprophylactic anticoagulant therapy, including heparin, low-molecular-weight heparin, and warfarin (for postpartum prophylaxis only)
2. Testing for inherited or acquired thrombophilias in women with a history of thrombosis or a family history of thrombosis, including:
  - Lupus anticoagulant
  - Anticardiolipin antibodies
  - Factor V Leiden mutation
  - Prothrombin G20210A mutation
  - AT-III antigen activity levels
  - Fasting homocysteine levels or the methylenetetrahydrofolate reductase (MTHFR) mutation
  - Protein C antigen activity levels
  - Protein S antigen activity levels (free and total)
3. Testing for deep vein thrombosis (DVT) and pulmonary embolism (PE)

## MAJOR OUTCOMES CONSIDERED

- Effectiveness of thromboprophylaxis for preventing venous thromboembolism
- Prophylactic-related maternal and neonatal morbidity and mortality

## METHODOLOGY

### METHODS USED TO COLLECT/SELECT EVIDENCE

Hand-searches of Published Literature (Primary Sources)  
 Hand-searches of Published Literature (Secondary Sources)  
 Searches of Electronic Databases

### DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' (ACOG's) own internal resources were used to conduct a literature search to locate relevant articles published between January 1985 and March 1998. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document.

Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles.

### NUMBER OF SOURCE DOCUMENTS

Not stated

### METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force.

I Evidence obtained from at least one properly designed randomized controlled trial

II-1 Evidence obtained from well-designed controlled trials without randomization

II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group

II -3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.

III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

## METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

## DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

## DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician-gynecologists were used. See also the "Rating Scheme for the Strength of Recommendations" field regarding Grade C recommendations.

## RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:

Level A - Recommendations are based on good and consistent scientific evidence.

Level B - Recommendations are based on limited or inconsistent scientific evidence.

Level C - Recommendations are based primarily on consensus and expert opinion.

## COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

## METHOD OF GUIDELINE VALIDATION

Internal Peer Review

## DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician-gynecologists generalists and sub-specialists. The final guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

The grades of evidence (I-III) and levels of recommendations (A-C) are defined at the end of "Major Recommendations."

The following recommendations are based primarily on consensus and expert opinion (Level C):

- Pregnant patients with a history of isolated venous thrombosis directly related to a transient, highly thrombogenic event (orthopedic trauma, complicated surgery) in whom an underlying thrombophilia has been excluded may be offered heparin prophylaxis or no prophylaxis during the antepartum period. However, they should be counseled that their risk of thromboembolism is likely to be higher than the normal population. Prophylactic warfarin should be offered for 6 weeks postpartum.
- Pregnant patients with a history of idiopathic thrombosis, thrombosis related to pregnancy or oral contraceptive use, or a history of thrombosis accompanied by an underlying thrombophilia other than homozygous for the factor V Leiden mutation, heterozygous for both the factor V Leiden and the prothrombin G20210A mutation, or antithrombin-III (AT-III) deficiency should be offered antepartum and postpartum low-dose heparin prophylaxis.
- Patients without a history of thrombosis but who have an underlying thrombophilia and have a strong family history of thrombosis also are candidates for antepartum and postpartum prophylaxis. At the minimum, postpartum prophylaxis should be offered.
- Pregnant patients with a history of life-threatening thrombosis, with recent thrombosis, with recurrent thrombosis, receiving chronic anticoagulation, or patients with thrombosis found to be AT-III deficient, homozygous for the factor V Leiden mutation or prothrombin G20210A mutation, heterozygous for both the factor V Leiden and the prothrombin G20210A mutation should be given adjusted-dose heparin every 8 hours to maintain the activated partial thromboplastin time (APTT) at least 1.5 times control throughout the dosing interval. Low-molecular-weight heparin (LMWH) administered twice daily also is an alternative.
- Patients at risk for thrombosis should receive warfarin postpartum for 6 weeks to achieve an international normalized ration (INR) of approximately 2.0 to 3.0. Heparin should be given immediately postpartum with warfarin for at least 5 days until the INR is therapeutic.
- Patients with antiphospholipid syndrome and a history of thrombosis require adjusted-dose prophylactic anticoagulation.
- Patients who are candidates for either prophylactic or therapeutic heparin may be given enoxaparin or dalteparin during pregnancy. However, because of the lack of data regarding adequate dosing during pregnancy, antifactor Xa levels may be monitored.

- The safety of epidural anesthesia with twice-daily dosing of LMWH is of concern and should be withheld until 24 hours after the last injection.
- Epidural anesthesia appears to be safe in women taking unfractionated low-dose heparin if the APTT is normal.

#### Definitions:

#### Grades of Evidence

I Evidence obtained from at least one properly designed randomized controlled trial

II-1 Evidence obtained from well-designed controlled trials without randomization

II-2 Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group

II-3 Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.

III Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

#### Levels of Recommendations

Level A - Recommendations are based on good and consistent scientific evidence.

Level B - Recommendations are based on limited or inconsistent scientific evidence.

Level C - Recommendations are based primarily on consensus and expert opinion.

#### CLINICAL ALGORITHM(S)

None provided

### EVIDENCE SUPPORTING THE RECOMMENDATIONS

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

### BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

#### POTENTIAL BENEFITS

Appropriate use of anticoagulant therapy to prevent venous thromboembolism in pregnant women

#### POTENTIAL HARMS

- The major concerns with heparin use during pregnancy are not fetal but maternal and include heparin-induced osteoporosis and heparin-induced thrombocytopenia (HIT). Bleeding is also an issue.
- Warfarin derivatives cross the placenta. A skeletal embryopathy resulting in stippled epiphyses and nasal and limb hypoplasia can occur when warfarin is given between 6 and 12 weeks of gestation. Midtrimester exposure may result in optic atrophy, microcephaly, and developmental delay. Bleeding can occur in the fetus at any time, resulting in a high fetal loss rate.

#### CONTRAINDICATIONS

##### CONTRAINDICATIONS

Warfarin derivatives cross the placenta and in most cases are relatively contraindicated in pregnancy

#### QUALIFYING STATEMENTS

##### QUALIFYING STATEMENTS

These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.

#### IMPLEMENTATION OF THE GUIDELINE

##### DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

#### INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

##### IOM CARE NEED

Staying Healthy

##### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

American College of Obstetricians and Gynecologists (ACOG). Thromboembolism in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2000 Aug. 10 p. (ACOG practice bulletin; no. 19). [73 references]

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2000 Aug (reviewed 2005)

### GUIDELINE DEVELOPER(S)

American College of Obstetricians and Gynecologists - Medical Specialty Society

### SOURCE(S) OF FUNDING

American College of Obstetricians and Gynecologists (ACOG)

### GUIDELINE COMMITTEE

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Not stated

### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Thromboembolism in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 1997 Mar. (ACOG educational bulletin number 234).

According to the guideline developer, this guideline is still considered to be current as of December 2005, based on a review of literature published that is performed every 18-24 months following the original guideline publication.



## GUIDELINE AVAILABILITY

Electronic copies: Not available at this time.

Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 4500, Kearneysville, WV 25430-4500; telephone, 800-762-2264, ext. 192; e-mail: [sales@acog.org](mailto:sales@acog.org). The ACOG Bookstore is available online at the [ACOG Web site](#).

## AVAILABILITY OF COMPANION DOCUMENTS

None available

## PATIENT RESOURCES

None available

## NGC STATUS

This NGC summary was completed by ECRI on September 14, 2004. The information was verified by the guideline developer on December 8, 2004.

## COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## DISCLAIMER

### NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006